EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudie

Differential Effects of Antihypertensive Drugs on Central Blood Pressure: A Randomized Comparison Between Nebivolol and Telmisartan

Subin Lim iD, Hyungdon Kook, Cheol Woong Yu, Ju Hyeon Kim iD, Jung-Joon Cha, Hyung Joon Joo, Jin Oh Na, Cheol Ung Choi, Sang Yup Lim, Jae Hyoung Park, Soon Jun Hong, Do-Sun Lim

American Journal of Hypertension · 01.02.2026 · 39 (2) · 303-311

DOI: 10.1093/ajh/hpaf098 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Hypertension, online erschienen am 10.06.2025. Verfasst von Subin Lim und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, Ewha Womans University Seoul Hospital, Seoul, Korea. Hauptthemen laut MEDLINE: Telmisartan, Nebivolol, Hypertension, Blood Pressure. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Hanyang University, ILDONG Pharmaceutical Co., Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Central blood pressure (CBP) is a better predictor of cardiovascular outcomes than peripheral blood pressure. First- and second-generation beta-blockers have shown poor CBP-lowering effects. However, nebivolol, a third-generation beta-blocker with vasodilatory effects, may be beneficial in lowering CBP. This study compared the CBP-lowering efficacies of nebivolol and telmisartan over a 12-week period in patients with hypertension. METHODS This prospective, randomized, multicenter, open-label, controlled trial evaluated 98 participants with hypertension. For 12 weeks, participants received either nebivolol (n = 49) or telmisartan (n = 49) for 12 weeks with a target blood pressure of ≤140/90 mmHg for the entire period. The primary endpoint was a change in central systolic blood pressure (cSBP) after 12 weeks. RESULTS cSBP reduction at week 12 was significantly less in the nebivolol group than in the telmisartan group (−17.2 vs. −29.3mmHg; between-group difference, 12.7 mmHg; 95% confidence interval [CI], 4.1–21.2; P = 0.004). Central pulse pressure decreased in both groups; however, the difference between the groups was not significant (−8.5 vs. −14.1 mmHg, P = 0.207). The nebivolol group demonstrated a slightly increased augmentation index (AIx), whereas the telmisartan group had a significantly decreased AIx (0.7 vs. −7.3 mmHg; 95% CI, 3.1–13.0; P = 0.002). Heart rate at week 12 was significantly lower in the nebivolol group than that in the telmisartan group (64.2 ± 11 vs. 74.6 ± 11 beats per minute, P < 0.001). CONCLUSIONS Nebivolol was less effective than telmisartan at reducing cSBP. Clinical Trial Registration NCT05328310

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TelmisartanNebivololHypertensionBlood PressureAngiotensin II Type 1 Receptor BlockersAntihypertensive AgentsAdrenergic beta-1 Receptor AntagonistsHumansMaleFemaleMiddle AgedAgedProspective StudiesTreatment OutcomeTime Factors

Stichwörter der Autor:innen

angiotensin receptor blockerbeta-blockerblood pressurecentral blood pressurehypertension

Substanzen

TelmisartanNebivololAngiotensin II Type 1 Receptor BlockersAntihypertensive AgentsAdrenergic beta-1 Receptor Antagonists

Autor:innen und Institutionen

  • Division of Cardiology, Department of Internal Medicine, Ewha Womans University Seoul Hospital, Seoul, Korea.
  • Division of Cardiology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.
  • Division of Cardiology, Department of Internal Medicine, College of Medicine, Hanyang University, Seoul, Korea.
  • Division of Cardiology, Department of Internal Medicine, Asan Medical Center, Seoul, Korea.
  • Division of Cardiology, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea.
  • Division of Cardiology, Department of Internal Medicine, Korea University Ansan Hospital, Ansan, Korea.

ORCID-Profile: Subin Lim, Ju Hyeon Kim

Förderung

  • Hanyang University
  • ILDONG Pharmaceutical Co., Ltd

Zitieren

APA

Lim, S., Kook, H., Yu, C. W., Kim, J. H., Cha, J. J., Joo, H. J., Na, J. O., Choi, C. U., Lim, S. Y., Park, J. H., Hong, S. J., & Lim, D. S. (2026). Differential Effects of Antihypertensive Drugs on Central Blood Pressure: A Randomized Comparison Between Nebivolol and Telmisartan. American Journal of Hypertension, 39(2), 303-311. https://doi.org/10.1093/ajh/hpaf098

Vancouver

Lim S, Kook H, Yu CW, Kim JH, Cha JJ, Joo HJ, et al. Differential Effects of Antihypertensive Drugs on Central Blood Pressure: A Randomized Comparison Between Nebivolol and Telmisartan. American Journal of Hypertension. 2026;39(2):303-311. doi:10.1093/ajh/hpaf098

BibTeX
@article{Lim2026,
  author = {Lim, Subin and Kook, Hyungdon and Yu, Cheol Woong and Kim, Ju Hyeon and Cha, Jung-Joon and Joo, Hyung Joon and Na, Jin Oh and Choi, Cheol Ung and Lim, Sang Yup and Park, Jae Hyoung and Hong, Soon Jun and Lim, Do-Sun},
  title = {Differential Effects of Antihypertensive Drugs on Central Blood Pressure: A Randomized Comparison Between Nebivolol and Telmisartan},
  journal = {American Journal of Hypertension},
  year = {2026},
  volume = {39},
  number = {2},
  pages = {303--311},
  doi = {10.1093/ajh/hpaf098}
}
Kostenlos starten →